Cel Sci Corporation (CVM)

[meirluc]

Thank you Biobonic. I am also looking forward to tomorrow.

Another thought that came to my mind is that given a minimum of 784 patients in the trial, the high risk chemo treated patients did so much
better than the low risk patients who did not get chemo. In that case, henceforth the low risk patients should also be treated with chemo unless they have a contraindicating medical condition. Theoretically, with chemo the low risk patients should be doing even better than the high risk patients.

That would obviate the use of Multikine for any of the patients.

Also, if we had a 5 year OS of about 67% in the high risk group, what does it say of CVM's 5 year estimate of a 55% mortality for the entire trial which translates to a 5 year OS of only 45%?

Speaking of way off, according to this scenario, CVM's OS estimate was 22% wrong (67%-45%=22%) and landed way out in left field.